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Abstract
Chronic inflammation, as a consequence of the persistent infection with Trypanosoma cruzi,
leads to continuous activation of the immune system in patients with chronic Chagas dis-
ease. We have previously shown that increased sera levels of soluble P-selectin are associ-
ated with the severity of the cardiomyopathy distinctive of chronic Chagas disease. In this
study, we explored the expression of biomarkers of platelet and endothelial activation, tissue
remodeling, and mediators of the coagulation cascade in patients at different clinical stages
of chronic Chagas heart disease. The frequencies of activated platelets, measured by the
expression of CD41a and CD62P were decreased in patients with chronic Chagas disease
compared with those in uninfected subjects, with an inverse association with disease sever-
ity. Platelet activation in response to adenosine diphosphate was also decreased in T. cruzi-
infected subjects. A major proportion of T. cruzi infected subjects showed increased serum
levels of fibrinogen. Patients with severe cardiac dysfunction showed increased levels of
endothelin-1 and normal values of procollagen I. In conclusion, chronic infection with T.
cruzi induced hemostatic alterations, even in those patients who do not yet present cardiac
symptoms.
Introduction
Trypanosoma cruzi, the causative agent of Chagas disease, infects 6–7 million people in Central
and South America, as well as in countries historically nonendemic for T. cruzi infection [1].
The acute phase is characterized by the presence of a large number of parasites in the circula-
tion and even though the immune response is able to control the infection, the parasite can
survive establishing a chronic infection.
Chronic inflammation, as a consequence of the persistent infection with T. cruzi, leads to
continuous activation of the immune system in chronic Chagas disease patients [2–5].
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Inflammatory mediators regulate the expression of different adhesion molecules that partici-
pate in the recruitment of leukocytes and monocytes to sites of infection [6]. Among the latter
group, platelet selectin (P-selectin) redistributes to the surface of platelets and endothelial cells
within minutes after activation [7–9], and the P-selectin glycoprotein ligand-1 (PSGL-1) is
constitutively expressed and participates in both leukocyte recruitment and the formation of
platelet thrombi [10].
We have previously shown that increased serum levels of soluble P-selectin are associated
with the severity of the cardiomyopathy that is distinctive of chronic Chagas disease [3]. How-
ever, children in early stages of T. cruzi infection also displayed high s-P-selectin titers, and
these levels decreased following treatment with benznidazole [11]. Although increased s-P-
selectin levels in chronic T. cruzi infection probably reflect alterations in the microcirculation
that might eventually result in a pathogenic mechanism, it can also be reflective of an ongoing
immune response to keep the parasite under control [3,12–15]. Of note, it is becoming more
evident that platelets have inflammatory functions and can influence both innate and adaptive
immune responses [16–18]. Here, we explored the expression of platelet and endothelial acti-
vation, tissue remodeling, and mediators of the coagulation cascade in patients at different
clinical stages of chronic Chagas heart disease. The findings reported in the present work show
platelet dysfunction and alterations in hemostatic factors in chronic Chagas disease.
Materials and methods
Selection of the study population
Subjects were recruited at the Chagas disease Section, Cardiology Department, Hospital Inter-
zonal General de Agudos “Eva Perón”, Buenos Aires, Argentina. A positive T. cruzi infection
was determined by indirect immunofluorescence assay, hemagglutination, and enzyme-linked
immunoassay techniques [19]. Subjects testing positive in at least two of these tests were con-
sidered to be infected. Chronically T. cruzi-infected subjects were evaluated clinically and
stratified according to a modified version of the Kuschnir grading system, as follows [20,21].
Group 0 (G0) had normal electrocardiograph (ECG), chest radiograph, and echocardiograph
findings; Group 1 (G1) had normal chest radiograph and echocardiograph findings but abnor-
mal electrocardiograph findings; Group 2 (G2) had ECG abnormalities and heart enlargement
as determined by chest X-ray; and Group 3 (G3) had ECG abnormalities, heart enlargement
and clinical or radiologic evidence of heart failure. For each experiment, age-matched unin-
fected healthy subjects were included as controls (Table 1). A group of patients suffering
from dilated cardiomyopathy of noninfectious origin was also evaluated as a control group
Table 1. Baseline characteristics of the study population.
Clinical stage n
Age range Sex
(median years) Female Male
Uninfected healthy subjects 35 18–76 (44) 20 15
G0 20 19–72 (42) 11 9
G1 16 25–67 (51.5) 7 9
G2 2 50–59 (54.5) 1 1
G3 14 42–76 (59) 3 11
HFA 9 34–81 (61) 1 8
Note.
A HF, Patients with heart failure not related to Chagas disease in a compensated state.
https://doi.org/10.1371/journal.pone.0218260.t001
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(Table 1). The inclusion criteria for heart failure (HF) patients were class I/II/III classification
(New York Heart Association classification), with an ejection fraction of< 40% by echocardi-
ography. The etiology for heart failure was hypertension in three patients, postchemotherapy
in one patient, alcoholism in one patient and idiopathic dilated cardiomyopathy in four
patients.
This protocol was approved by the Institutional Review Boards of the Hospital Interzonal
General de Agudos Eva Perón, Buenos Aires, Argentina. Patients with Chagas disease or unin-
fected controls with a history of hypertension, vascular, ischemic or congenital heart disease,
cancer, HIV infection, syphilis, diabetes, arthritis or allergy, and with coagulation disorders
were excluded from the study. Signed informed consent was obtained from all individuals
prior to inclusion in the study.
Collection of plasma and serum specimens
Five milliliters of blood was collected by venipuncture into tubes containing sodium citrate
(Vacutainer; Becton Dickinson). To obtain plasma, blood was centrifuged at 1400 g for 20 min
at 25˚C. Blood to be used for serum analysis was allowed to coagulate at 4˚C and centrifuged
at 1000 g for 15 min for sera separation. Samples were stored at -80˚C until use. Due to sample
availability, assays were not run for all the samples.
Detection of P-selectin (CD62P), CD63 and PSGL-1 expression in whole
blood
Monoclonal antibodies were all purchased from Becton Dickinson. To measure the expression
of P-selectin and CD63 in platelets, 5 μl of whole blood collected in citrate-containing tubes
was diluted with 50 μl of PBS solution and stained with anti-CD41a (FITC-conjugated) and
anti-CD62P (PE-conjugated) or anti-CD63 (PE-conjugated) monoclonal antibodies at room
temperature in the dark for 20 min. Unstained samples were used as negative controls. Blood
samples were fixed with 1% paraformaldehyde at 4˚C for 30 min and analyzed on a FACSCali-
bur flow cytometer using CellQuest software (Becton Dickinson). Platelets were identified by
side scatter and anti-CD41a-FITC immunofluorescence on a logarithmic-scaled dot plot. Ten
thousand events gated on CD41a+ cells were collected per sample. Data are shown as the per-
centage of CD41a+ cells that express CD62 or CD63. For expression of PSGL-1 (CD162),
100 μl of whole blood was stained with anti-CD4 (PerCP-conjugated), anti-CD8 (FITC-conju-
gated) and anti-CD162 (PE-conjugated) monoclonal antibodies at room temperature in dark
for 20 min. Subsequently, a FACS lysing solution (Becton Dickinson) was added, followed by
two wash steps and fixation with 1% paraformaldehyde. Two hundred thousand events were
collected. For analysis, lymphocytes were gated by forward and side-scatter parameters, and
the percentage of CD4+CD162+ or CD8+CD162+ cells were calculated for each patient.
Measurements of mediators of the coagulation cascade and endothelial
activation
The platelet counts were measured using optical automated hematological counter Cell-Dyn
Ruby (Abbot). Fibrinogen was measured by the Clauss technique using the STA-Liquid Fib
reagents (Stago) [22], whereas the von Willebrand factor was determined by a turbidimetric
method using the commercial kit LIATEST-VWF:Ag (Stago). Controls and calibrators for
fibrinogen and von Willebrand measurement were from Stago and samples were analyzed
with an automated coagulation analyzer STA Compact (Stago). Plasma levels of endothelin-1
(R & D Systems) and serum levels of procollagen I C-terminal propeptide (Takara Bio Inc.)
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were measured by capture ELISA using commercial kits and according to the manufacturer’s
instructions.
Measurement of platelet activation and platelet-leukocyte aggregation
Five microliters of whole blood was incubated with adenosine diphosphate (ADP) at a final
concentration of 20 μmol/L at room temperature for 5 min. A control incubation was per-
formed similarly, except that ADP was omitted. Then, samples were stained with anti-CD41a
(FITC-conjugated) and anti-CD62P (PE-conjugated) monoclonal antibodies at room temper-
ature in dark for 20 min. Blood samples were fixed with 1% paraformaldehyde at 4˚C for 30
min and analyzed on a FACSCalibur flow cytometer using CellQuest software (Becton Dickin-
son). Platelets were identified by side scatter and anti-CD41a-FITC immunofluorescence on a
logarithmic-scaled dot plot. Ten thousand events gated on CD41a+ cells were collected per
sample. Data are shown as the percentage of CD41a+ cells that express CD62.For platelet-leu-
kocyte aggregation assays, 50 microliters of whole blood was incubated with anti-CD41a (PE-
conjugated) and anti-CD45 (FITC-conjugated) monoclonal antibodies at room temperature
in dark for 20 min. Next, samples were fixed with 1% paraformaldehyde at 4˚C for 30 min and
analyzed on a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson)
[23,24]. Lymphocytes were identified based on cell size and granularity using the forward and
side scatter. The analysis of CD45-FITC vs. CD41a-PE allowed the discrimination of platelet-
coupled and platelet-free lymphocytes. Data are shown as the percentage of platelet-coupled
lymphocytes in the lymphocyte population.
Statistical analyses
Normality of the variables distribution was assessed using the Kolmogorov-Smirnov criterion.
Differences between T. cruzi-infected and uninfected subjects were evaluated by Mann-Whit-
ney U test or Student’s t test (two-tailed). Differences among groups were evaluated by
ANOVA followed by a Bonferroni’s test for multiple comparisons or by a test for lineal trends.
Correlation between variables was performed with the Pearson test. Differences were consid-
ered statistically significant when P values were< 0.05.
Results
Quantification of activated platelets and the counter-receptor on T cells in
patients with chronic Chagas disease
Platelet levels measured by platelet counts were not altered in patients with chronic Chagas
disease compared with uninfected subjects (Fig 1A). Nevertheless, some patients with cardio-
myopathy had decreased platelet counts. Likewise, platelet counts measured by the expression
of CD41a (Fig 1B) in whole blood, were decreased in patients with chronic Chagas disease
compared with those in uninfected healthy subjects, with an inverse association with disease
severity (Fig 1B). The CD41a expression per cell, determined by the mean fluorescence inten-
sity (MFI) measurement, was not altered in subjects chronically infected with T. cruzi com-
pared with that in uninfected healthy controls (S1 Fig). The percentage of platelets (CD41a+)
that express the activation marker CD62P was diminished in chronically infected subjects, par-
ticularly in those subjects with signs of cardiac dysfunction (i.e., G1, G2 and G3 patient
groups) [Fig 2A–2C]. Not only was the percentage of CD41a+CD62P+ cells diminished but
also the CD62P MFI decreased in subjects chronically infected with T. cruzi (Fig 2D). In con-
trast, no significant differences were observed in the expression of platelet activation marker
CD63 (Fig 2E and 2F). Likewise, the expression of P-selectin counter-receptor PSGL-1 was not
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altered on CD4+ and CD8+ T cells of Chagas disease patients when compared with that of
uninfected healthy subjects (S2 Fig).
Assessment of platelet function in subjects chronically infected with T.
cruzi
To assess platelet function, we measured the expression of P-selectin after ADP stimulation in
blood samples collected from T. cruzi-infected and uninfected healthy subjects. The percentage
of activated platelets after the stimulation was lower in the T. cruzi-infected group than that in
the uninfected control group (Fig 3A and 3B).
Because several studies have shown that platelet levels mildly decrease with age while plate-
let activation increases [25], we performed a correlation analysis between age and the fre-
quency of activated platelets in the T. cruzi-infected and uninfected groups. The frequencies of
activated platelets were positively correlated with the age of uninfected healthy subjects (Fig 4B
and 4D), but this correlation was abolished in T. cruzi-infected subjects (Fig 4A and 4C). No
significant differences in the percentages of platelet- lymphocyte aggregation were observed
between T. cruzi-infected and uninfected subjects (S3 Fig).
Measurements of mediators of the coagulation cascade and endothelial
activation
To address whether patients with chronic Chagas disease have alterations in their hemostasis,
the von Willebrand and fibrinogen factors were measured. Seven out of 19 patients showed
von Willebrand (Fig 5A) levels above the reference concentration while other five patients had
increased fibrinogen (Fig 5B) levels. Only one patient showed a concomitant increase in both
molecules accounting for a total of 11 out of 19 (58%) patients with at least one molecule
altered.
Fig 1. Quantification of platelets in patients with chronic Chagas disease. Platelet levels were measured by platelet counts, using an optical automated
hematological counter (Fig 1A) and by the expression of CD41a (Fig 1B) determined by flow cytometry in whole blood samples. Each symbol represents
the number of platelets per ml (Fig 1A) or the percentage of CD41a+ cells (Fig 1B). Median values are indicated by the horizontal lines. �P� 0.05 and
��p� 0.01 calculated by an ANOVA test followed by a Bonferroni test for multiple comparisons. The oblique line indicates a significant tendency between
medians calculated using a test for lineal trends. The full-black symbols represent patients belonging to stages G2 and G3.
https://doi.org/10.1371/journal.pone.0218260.g001
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Increased plasma levels of endothelin-1, which is a marker of endothelial activation, were
also found in Chagas disease patients with severe cardiac dysfunction, compared with those in
uninfected subjects (Fig 6). Of note, increased endothelin-1 levels in some T. cruzi-infected
patients concurred with increased levels of fibrinogen or the von Willebrand factor and with
decreased levels of activated platelets (Table 2).
Serum levels of the tissue remodeling factor procollagen I C-terminal propeptide inversely
correlated with the severity of the cardiac disease in T. cruzi-infected subjects (Fig 7). The level
of endothelial activation and tissue remodeling was also evaluated in a group of patients with
heart failure of noninfectious etiology. The levels of endothelin-1 and procollagen 1 in these
patients were similar to those found in T. cruzi-infected subjects with severe cardiac disease
(Figs 6 and 7).
Discussion
Platelets, which participate in thrombotic processes, have different roles in vascular biology
and in the immune response, including protective functions and other functions that would
contribute to an adverse inflammatory state [26]. Our results showed alterations in the levels
and function of platelets, tissue remodeling and endothelial activation in chronically infected
patients, even in those patients who do not yet present with cardiac symptoms. The negative
trend between the percentages of platelets and disease severity might be explained either by a
Fig 2. Flow cytometric analysis of activated platelet surfaces. Whole blood was labelled with CD41a, CD62P (P-selectin), CD63 monoclonal
antibodies and analyzed by flow cytometry. (A) Platelets were identified by their characteristic side-scatter properties (granularity: x-axis) and positive
labeling with a platelet-specific mAb reagent (CD41a-FITC: y-axis). (B) Histogram plots overlaid by unstained, uninfected controls and G3 patient
CD62P-PE (x-axis) fluorescence of the events within the “R1” gate were further analyzed. (C) Percentage of CD41a+CD62P+ and (E) CD41a+CD63+
cells and the mean fluorescence intensity (MFI) of the (D) CD41a+CD62P+ and (F) CD41a+CD63+ expression in each of the chronic Chagas disease
patients with different clinical forms of the disease studied. Median values are indicated by the horizontal lines. �P< 0.05 and was calculated by Mann-
Whitney test. The oblique line indicates a significant tendency between medians calculated using a test for lineal trends. The symbols in black represent
patients belonging to stages G2 and G3.
https://doi.org/10.1371/journal.pone.0218260.g002
Fig 3. Determination of platelet activation in whole blood of patients with chronic Chagas disease. The percentages of platelets before and after the addition of ADP
were measured by flow cytometry. (A) The symbols represent the expression of CD41a+CD62P+ at the basal levels or after the activation with ADP. ���P<0.001 vs the
nonstimulated uninfected healthy group and calculated by using a paired t test. (B) Activation index (expression of CD41a+CD62P+ cells after activation/basal
expression of CD41a+CD62P+ cells) in each of the subjects evaluated. ��P< 0.001 and calculated by using the Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0218260.g003
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platelet activation with shortening of survival or by impaired platelet production in the bone
marrow. P-selectin (CD62P) is a protein that mediates adhesion of leukocytes to the endothe-
lium and in the aggregation of platelets. After being activated by agonist including thrombin,
collagen and adenosine diphosphate), the molecules stored in the alpha-granules in platelets or
in the Weibel-Palade bodies in endothelial cells are exposed in the cell surface [16,27].
We have previously shown that soluble P-selectin levels are increased in the circulation of
patients with chronic Chagas disease [3], supporting the idea that increased platelet activation
might in turn induce the release of P-selectin in a way that regulates exacerbated platelet acti-
vation [9,28]. The decreased levels of P-selectin-expressing platelets in patients with signs of
cardiac dysfunction observed in this study are in agreement with the higher levels of soluble P-
selectin observed in more severe stages of chronic Chagas disease [3]. In contrast, the expres-
sion of the activation molecule CD63 was similar between chronic chagasic patients and unin-
fected control, which could be due to the fact that it is a molecule that is not preformed as P-
selectin and is not cleaved following activation [29].
Platelet loss is a common feature in viral [30] and bacterial infections [31,32]. Here, we pro-
vide further support that such a loss might also occur in parasitic infections. Supporting the
relationship between infection and platelet loss is the observation of a positive association
between platelet activation and age in uninfected subjects, an association that is lost in T.
cruzi-infected subjects. Although activated platelets can contribute to an increased risk of
Fig 4. Association between platelet activation and age in patients with chronic Chagas disease and uninfected
healthy subjects. Correlation analysis between the levels of activated platelets and age was performed by the Pearson
correlation test in T. cruzi-infected subjects (A, n = 24; C, n = 14) and uninfected healthy subjects (B, n = 17; D, n = 18).
https://doi.org/10.1371/journal.pone.0218260.g004
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thrombotic events [33], they might also be important in host defense. Thus, upon activation,
platelets release a range of chemokines that attract and activate leukocytes and concurrently,
various platelet surface molecules (i.e., P-selectin and GPIIb/IIIa). The proinflammatory
Fig 5. Plasma levels of von Willebrand factor and fibrinogen in patients with chronic Chagas disease. The symbols represent the concentration of (A)
von Willebrand factor and (B) fibrinogen for each individual evaluated in the different clinical groups determined. The dotted line shows the maximum
reference value (normal range of von Willebrand = 50–160%; normal range of fibrinogen = 200–400 mg/dl). The symbols in black represent patients
belonging to stages G2 and G3.
https://doi.org/10.1371/journal.pone.0218260.g005
Fig 6. Levels of endothelin-1 in patients with chronic Chagas disease. Plasma endothelin-1 levels were determined
by capture ELISA. The symbols represent the concentration of endothelin-1 for each individual evaluated. The
horizontal lines indicate the values of the medians for each clinical group established by the Kuschnir classification, as
indicated in Materials and Methods. HF, patients with heart failure of origin not related to Chagas disease. �P� 0.05
and was calculated by the unpaired t test.
https://doi.org/10.1371/journal.pone.0218260.g006
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cytokines IL-1 and TGF-beta mediate the crosstalk with endothelial cells and leukocytes in
order to activate them and facilitate transendothelial migration at sites of injury or inflamma-
tion [34–39]. Platelets might also release superoxide, peroxide and hydroxyl radicals upon acti-
vation [40] and exert phagocytotic activity [41,42]. Here, we demonstrate that not only the
frequencies of platelets but also their functions are impaired in subjects chronically infected
with T. cruzi. Of note, we did not find increased platelet-lymphocyte aggregation more likely
in line with the gradually impairment of the immune response in the chronic phase rather
than a pro-thrombotic state of chronically T. cruzi-infected subjects.
In our study, we found that 11 out of 19 patients had increased levels of the von Willebrand
factor or fibrinogen and that these levels were not restricted to the most severe forms of the
disease. In contrast, we did find increased levels of endothelin-1 in the more severe forms of
chronic Chagas disease, which was consistent with the findings in uninfected subjects suffering
Table 2. Alterations of prothrombotic markers in T. cruzi-infected patients.
Clinical stage Endothelin-1 (pg/ml) Von Willebrand (%) Fibrinogen (mg%) CD41a+CD62+ (%)
G0 6.09 185 394 8.32
G0 12.29 115 284 17.71
G0 7.76 58 424 14.57
G0 9.50 132 491 ND
G1 9.13 174 315 13.19
Note. The values in healthy individuals are the following: Endothelin-1, median ± SD = 3.2 ± 1.11 (pg/ml); von Willebrand (VB), range = 50–160%; Fibrinogen,
range = 200–400 mg%; and CD41a+CD62+, median ± SD = 34 ± 13%. Patients 1–5 displayed increased endothelin-1 levels.
https://doi.org/10.1371/journal.pone.0218260.t002
Fig 7. Procollagen levels in patients with chronic Chagas disease. The levels of procollagen peptides were measured
by capture ELISA. The symbols represent the concentration of procollagen for each individual evaluated in the
different clinical groups determined by the Kuschnir classification, as indicated in Materials and Methods. The
horizontal lines show the median. HF, patients with heart failure unrelated to Chagas disease. �P� 0.05 and was
calculated by the unpaired t test. The oblique line indicates a significant tendency between medians using a test for
lineal trends; P = 0.0006.
https://doi.org/10.1371/journal.pone.0218260.g007
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from heart failure, who are known to present with neurohormonal activation and a high
degree of endothelial injury [43,44]. Of note, some patients in the asymptomatic stage also had
increased levels of endothelin-1 in association with increased levels of the von Willebrand fac-
tor which is synthesized and stored not only in megakaryocytes but also in endothelial cells.
Although it is possible that this increase reflects a state of greater immune activation as a con-
sequence of the release of mediators that activate the endothelium, we cannot rule out an
increased risk of progression in these patients. High endothelial activation in chronically T.
cruzi-infected subjects is also supported by increased soluble VCAM-1 (vascular cell adhesion
protein 1 molecule) levels observed in these patients [3]. Of note, concomitant increases of
fibrinogen and the von Willebrand factor was hardly observed supporting the idea that various
coagulation pathways can be altered in different patients with chronic Chagas disease. The von
Willebrand factor might participate in both primary and secondary hemostasis [45].
Other authors have evaluated a group of hypercoagulable biomarkers in patients with
chronic Chagas disease, demonstrating that fragments of prothrombin 1 + 2, endogenous
potential thrombin, the plasmin-antiplasmin complex (PAP) and soluble P-selectin levels were
increased in subjects chronically infected with T. cruzi [11,46–48] and that these alterations
decreased after a specific treatment with benznidazole [11,48]. In the experimental infection in
mice, an increase in the levels of thromboxane A2 and endothelin-1 associated with enhanced
platelet adherence and aggregation was also reported [49,50].
The higher levels of collagen I propeptides in infected subjects with less severe forms of the
disease might be related to the homeostatic process of remodeling as a consequence of the
immune response. Fibrosis, which is the consequence of a wrong process of tissue remodeling,
can arise if the damage persists, since inflammation can change the triggers from a reparative
response to a profibrotic harmful response in an attempt to continue repair [51]. Therefore,
under pathological conditions, the composition and amount of collagens change [52,53]. It is
known that patients with decompensated heart failure have elevated levels of collagen I pro-
peptides as a result of an acute tissue injury and that the levels return to normal values in the
compensated stage [54], which is in agreement with our findings presented in this study. Tis-
sue remodeling in the more severe stages of chronic Chagas disease likely involved the partici-
pation of other collagen types. Importantly, an increased ratio of collagen types I, III and V vs
collagen type IV, rather than their absolute amount, determines epithelial and endothelial cell
dysfunction in liver fibrosis [55]. Moreover, collagens play a direct role in hemostasis by their
interactions with platelet receptors, contributing to platelet spreading and activation [56],
which might also change in the chronic phase of T. cruzi infection.
Although the alterations observed in the different markers evaluated could be interpreted
as a state of greater risk to thrombotic processes, it is likely that these are indicators of a sus-
tained immune response. In previous studies, we have shown that the persistence of T. cruzi is
able to induce a process of functional depletion of T lymphocytes that is more pronounced as
the disease progresses [57]. The findings in the present study, support that platelets dysfunc-
tion, endothelial activation and altered tissue remodeling are induced by persistent infection
with T. cruzi.
Supporting information
S1 Fig. Expression of CD41a in platelets of patients with chronic Chagas disease. Whole
blood was stained with the CD41a monoclonal antibody and analyzed by flow cytometry. Each
symbol represents the Mean Fluoresce Intensity (MFI) of CD41a+ cells. The horizontal lines
indicate the values of the medians for each clinical group established by the Kuschnir classifi-
cation, as indicated in Materials and Methods. The symbols in black represent patients
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belonging to clinical stages G2 and G3.
(TIF)
S2 Fig. Expression of PSGL-1 in patients with chronic Chagas disease. A whole blood label-
ing was made in citrate using specific antibodies for CD4, CD8 and PSGL-1, and the samples
were analyzed by flow cytometry. Each symbol represents the percentage of CD4 (A) or CD8
(B) lymphocytes expressing PSGL-1 (left panel A and B) and the mean expression per cell of
PSGL-1 (right panel A and B) for each individual evaluated. The horizontal lines indicate the
values of the medians for each clinical group established by the Kuschnir classification, as indi-
cated in Materials and Methods.
(TIF)
S3 Fig. Analysis of platelet-lymphocytes aggregation in chronic Chagas disease patients.
Whole blood was stained with the CD41a and CD45 monoclonal antibodies and analyzed by
flow cytometry. Lymphocytes were identified based on cell size and granularity using the for-
ward and side scatter and the percentages of CD45 vs. CD41a were determined. The horizontal
lines indicate the values of the medians for each group.
(TIF)
S1 File. Raw data of the manuscript.
(XLSX)
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